Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.creatorArredondo, J. (Jorge)-
dc.creatorSimó, V. (Vicente)-
dc.creatorTejedor, P. (Patricia)-
dc.creatorJiménez, L. M. (Luis Miguel)-
dc.creatorHernán, C. (Cristina)-
dc.creatorZorrilla, J. (Jaime)-
dc.creatorLapuente, F. (Fernando)-
dc.creatorPastor, C. (Carlos)-
dc.date.accessioned2024-01-30T12:52:47Z-
dc.date.available2024-01-30T12:52:47Z-
dc.date.issued2021-
dc.identifier.citationArredondo, J. (Jorge); Simó, V. (Vicente); Tejedor, P. (Patricia); et al. "Oncological safety of transanal total mesorectal excision (TaTME) for rectal cancer: mid-term results of a prospective multicentre study". Surgical Endoscopy. 35, 2021, 1808 - 1819es_ES
dc.identifier.urihttps://hdl.handle.net/10171/68659-
dc.description.abstractBackground There is no consensus regarding the gold standard technique for rectal cancer as Total Mesorectal Excision (TME) may be safely performed either by open or minimally invasive surgery. The laparoscopic approach, however, may carry technical difficulties. For this reason, a novel technique has emerged in the last decade combining a dual laparoscopic dissection (abdominal and transanal) to perform the TME technique (TaTME). When focusing on oncological outcomes, there is a lack of literature regarding mid-long term results. The aim of this study is to evaluate the mid-term oncological impact of TaTME for treating rectal cancer. Methods A prospective multicentre study was performed in four tertiary centres including consecutive patients who underwent TaTME for mid-low rectal cancer by the same group of experienced surgeons. The analysed data included pathological results on the quality of TME and mid-term oncological outcomes. Results In total, 173 patients were included throughout a study period of 6 years. Our series included 70% males and 68% of patients with neoadjuvant treatments. The median follow-up was 23 [15–37.5] months. Regarding pathological results, a complete TME was achieved in 72.8%, while circumferential and distal margins were affected in 1.4 and 1.1%, respectively. Five patients developed local recurrences (3%) and 8.1% presented distant disease during the follow-up. The 2-year disease-free survival and the overall survival rates were 88% and 95%, respectively. Conclusions There is currently a lack of evidence in the literature regarding TaTME and oncological outcomes with no data available from randomized clinical trials. In the meantime, the reported results from different multicentre series are controversial. This study showed positive mid-term outcomes at 2 years of follow-up and supported notable oncological outcomes with TaTME. However, it must be emphasized that previous experience in minimally invasive and transanal surgeries is essential for surgeons before intending to perform TaTME.es_ES
dc.language.isoenges_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectLaparoscopic surgeryes_ES
dc.subjectRectal canceres_ES
dc.subjectTransanal total mesorectal excisiones_ES
dc.subjectTaTMEes_ES
dc.subjectTotal mesorectal excisiones_ES
dc.titleOncological safety of transanal total mesorectal excision (TaTME) for rectal cancer: mid-term results of a prospective multicentre studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://link.springer.com/article/10.1007/s00464-020-07579-4es_ES
dc.editorial.note© Springer Science+Business Media, LLC, part of Springer Nature 2020es_ES
dadun.citation.endingPage1819es_ES
dadun.citation.publicationNameSurgical Endoscopyes_ES
dadun.citation.startingPage1808es_ES
dadun.citation.volume35es_ES

Ficheros en este ítem:
Vista previa
Fichero
s00464-020-07579-4.pdf
Descripción
Tamaño
1.18 MB
Formato
Adobe PDF


Estadísticas e impacto
0 citas en
0 citas en

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.